Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7973185 | 1.00 | MEN1 (0.49) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL7804804 | 0.86 | MEN1 (0.53) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL26580348 | 0.85 | ALDH1A1 (0.46) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL16699597 | 0.85 | ALDH1A1 (0.46) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL30707625 | 0.85 | ALDH1A1 (0.59) | MEN1KMT2ATSHRALDH1A1OPRM1 | |
| SCHEMBL16700405 | 0.84 | GAA (0.47) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL22209990 | 0.84 | MEN1 (0.48) | MEN1KMT2AMAPTTSHRALDH1A1 | |
| SCHEMBL21513191 | 0.83 | TMEM97 (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12697262 | 0.83 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL12613037 | 0.81 | BCHE (0.42) | MEN1KMT2AALDH1A1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874209-B | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-114874209-A | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110461838-B | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| CN-110461838-A | oxadiazole transient receptor potential channel inhibitors | HOFFMANN LA ROCHE | 2019-11-15 | — | — | CN | disclosed |
| WO-2018162607-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-09-13 | — | — | WO | disclosed |
| US-6291520-B1 | INHIBIT THE ENZYME LIPOXYGENASE; TREATMENT OR ALLEVIATION OF INFLAMMATORY DISEASES, ALLERGIC CONDITIONS AND CARDIOVASCULAR DISEASES | PFIZER | 2001-09-18 | — | — | US | disclosed |
| EP-0559743-B1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER (US) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | MEN1 4744/4885KMT2A 4452/4885MAPT 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.